These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 27037630)

  • 1. Batch-to-batch pharmacokinetic variability confounds current bioequivalence regulations: A dry powder inhaler randomized clinical trial.
    Burmeister Getz E; Carroll KJ; Jones B; Benet LZ
    Clin Pharmacol Ther; 2016 Sep; 100(3):223-31. PubMed ID: 27037630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Between-Batch Pharmacokinetic Variability Inflates Type I Error Rate in Conventional Bioequivalence Trials: A Randomized Advair Diskus Clinical Trial.
    Burmeister Getz E; Carroll KJ; Mielke J; Benet LZ; Jones B
    Clin Pharmacol Ther; 2017 Mar; 101(3):331-340. PubMed ID: 27727445
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic Models for Inhaled Fluticasone Propionate and Salmeterol Xinafoate to Quantify Batch-to-Batch Variability.
    Li S; Feng K; Lee J; Gong Y; Wu F; Newman B; Yoon M; Fang L; Zhao L; Gobburu JVS
    AAPS J; 2024 Apr; 26(3):56. PubMed ID: 38671158
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population pharmacokinetics of fluticasone propionate/salmeterol using two different dry powder inhalers.
    Soulele K; Macheras P; Silvestro L; Rizea Savu S; Karalis V
    Eur J Pharm Sci; 2015 Dec; 80():33-42. PubMed ID: 26296862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of fluticasone propionate and salmeterol delivered as a combination dry powder via a capsule-based inhaler and a multi-dose inhaler.
    Mehta R; Daley-Yates PT; Jenkins K; Bianco J; Stylianou A; Louey MD; Chan RH
    Pulm Pharmacol Ther; 2014 Oct; 29(1):66-73. PubMed ID: 25035069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and pharmacodynamics of fluticasone propionate and salmeterol delivered as a combination dry powder from a capsule-based inhaler and a multidose inhaler in asthma and COPD patients.
    Daley-Yates PT; Mehta R; Chan RH; Despa SX; Louey MD
    J Aerosol Med Pulm Drug Deliv; 2014 Aug; 27(4):279-89. PubMed ID: 24074143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of Salmeterol and Fluticasone Propionate Delivered in Combination via Easyhaler and Diskus Dry Powder Inhalers in Healthy Subjects.
    Kirjavainen M; Mattila L; Vahteristo M; Korhonen J; Lähelmä S
    J Aerosol Med Pulm Drug Deliv; 2018 Oct; 31(5):290-297. PubMed ID: 29493402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Equivalent Systemic Exposure to Fluticasone Propionate/Salmeterol Following Single Inhaled Doses from Advair Diskus and Wixela Inhub: Results of Three Pharmacokinetic Bioequivalence Studies.
    Haughie S; Allan R; Wood N; Ward J
    J Aerosol Med Pulm Drug Deliv; 2020 Feb; 33(1):34-42. PubMed ID: 31364911
    [No Abstract]   [Full Text] [Related]  

  • 9. Can Pharmacokinetic Studies Assess the Pulmonary Fate of Dry Powder Inhaler Formulations of Fluticasone Propionate?
    Hochhaus G; Chen MJ; Kurumaddali A; Schilling U; Jiao Y; Drescher SK; Amini E; Berger SM; Kandala B; Tabulov C; Shao J; Seay B; Abu-Hasan MN; Baumstein SM; Winner L; Shur J; Price R; Hindle M; Wei X; Carrasco C; Sandell D; Oguntimein O; Kinjo M; Delvadia R; Saluja B; Lee SL; Conti DS; Bulitta JB
    AAPS J; 2021 Mar; 23(3):48. PubMed ID: 33768368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative pulmonary function and pharmacokinetics of fluticasone propionate and salmeterol xinafoate delivered by two dry powder inhalers to patients with asthma.
    Harrison LI; Novak CC; Needham MJ; Ratner P
    J Aerosol Med Pulm Drug Deliv; 2011 Oct; 24(5):245-52. PubMed ID: 21671752
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In Vitro, Pharmacokinetic, Pharmacodynamic, and Safety Comparisons of Single and Combined Administration of Tiotropium and Salmeterol in COPD Patients Using Different Dry Powder Inhalers.
    Horhota ST; van Noord JA; Verkleij CB; Bour LJ; Sharma A; Trunk M; Cornelissen PJ
    AAPS J; 2015 Jul; 17(4):871-80. PubMed ID: 25794622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic study for the establishment of bioequivalence of two inhalation treatments containing budesonide plus formoterol.
    Grekas N; Athanassiou K; Papataxiarchou K; Rizea Savu S; Silvestro L
    J Pharm Pharmacol; 2014 Dec; 66(12):1677-85. PubMed ID: 25109416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An Acoustic-Based Method to Detect and Quantify the Effect of Exhalation into a Dry Powder Inhaler.
    Holmes MS; Seheult JN; O'Connell P; D'Arcy S; Ehrhardt C; Healy AM; Costello RW; Reilly RB
    J Aerosol Med Pulm Drug Deliv; 2015 Aug; 28(4):247-53. PubMed ID: 25393346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic analysis of inhaled salmeterol in asthma patients: Evidence from two dry powder inhalers.
    Soulele K; Macheras P; Karalis V
    Biopharm Drug Dispos; 2017 Oct; 38(7):407-419. PubMed ID: 28374512
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Flow Rate on In Vitro Aerodynamic Performance of NEXThaler(®) in Comparison with Diskus(®) and Turbohaler(®) Dry Powder Inhalers.
    Buttini F; Brambilla G; Copelli D; Sisti V; Balducci AG; Bettini R; Pasquali I
    J Aerosol Med Pulm Drug Deliv; 2016 Apr; 29(2):167-78. PubMed ID: 26355743
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of fluticasone propionate and salmeterol hydrofluoroalkane inhalation aerosol on asthma-related quality of life.
    Edin HM; Andersen LB; Schoaf L; Scott-Wilson CA; Ho SY; Ortega HG
    Ann Allergy Asthma Immunol; 2009 Apr; 102(4):323-7. PubMed ID: 19441604
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of fluticasone propionate multidose, inhalation-driven, novel, dry powder inhaler versus a prevailing dry powder inhaler and a metered-dose inhaler.
    Gillespie M; Song S; Steinfeld J
    Allergy Asthma Proc; 2015; 36(5):365-71. PubMed ID: 26314817
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic, pharmacodynamic, efficacy, and safety data from two randomized, double-blind studies in patients with asthma and an in vitro study comparing two dry-powder inhalers delivering a combination of salmeterol 50 microg and fluticasone propionate 250 microg: implications for establishing bioequivalence of inhaled products.
    Daley-Yates PT; Parkins DA; Thomas MJ; Gillett B; House KW; Ortega HG
    Clin Ther; 2009 Feb; 31(2):370-85. PubMed ID: 19302910
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of a 12-week therapy with a new formulation of fluticasone propionate at doses of 125 and 250 μg administered through a new generation cyclohaler twice daily, in comparison to fluticasone propionate 500 μg dry powder inhaler twice daily in patients with moderate asthma.
    Kupryś-Lipińska I; Tworek D; Vanderbist F; Bocheńska-Marciniak M; Kuna P
    Pneumonol Alergol Pol; 2013; 81(6):527-36. PubMed ID: 24142782
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bioequivalence of budesonide plus formoterol (BF) Spiromax® and BF Turbohaler® (with and without charcoal block) in healthy volunteers.
    Weisfeld L; Shu Y; Shah TP
    Int J Clin Pharmacol Ther; 2015 Jul; 53(7):593-602. PubMed ID: 26042485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.